Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methoclopramide Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility to improve dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has recently announced the approval of its application for Methoclopramide Hydrochloride [1] - The drug is primarily indicated for the relief of nausea and vomiting [1] - Additionally, it can aid in enhancing gastrointestinal motility, addressing issues such as dyspepsia and delayed gastric emptying [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methoclopramide Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility to improve dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211) announced the receipt of the approval notice for Methoclopramide Hydrochloride from the National Medical Products Administration [1] - The drug is primarily indicated for the relief of nausea and vomiting [1] - Additionally, it can aid in enhancing gastrointestinal motility, addressing issues such as dyspepsia and delayed gastric emptying [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methochlorpromazine Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility for improving dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has announced the approval of Methochlorpromazine Hydrochloride, indicating a significant milestone in its product development pipeline [1] - The drug is primarily indicated for the treatment of nausea and vomiting, which could enhance the company's portfolio in the gastrointestinal therapeutic area [1] Industry Summary - The approval of Methochlorpromazine Hydrochloride reflects ongoing regulatory support for new pharmaceutical products in the market, highlighting the importance of innovative treatments for common gastrointestinal issues [1] - The use of dopamine receptor antagonists in managing gastrointestinal symptoms underscores the growing demand for effective therapies in this segment [1]

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Metoclopramide Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility to improve dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211.SZ) has announced the receipt of a marketing approval notification for Metoclopramide Hydrochloride [1] - The drug is primarily indicated for the relief of nausea and vomiting [1] - Additionally, it can aid in enhancing gastrointestinal motility, addressing issues such as dyspepsia and delayed gastric emptying [1]

证券代码：301211 证券简称：亨迪药业 公告编号：2025-041 湖北亨迪药业股份有限公司 关于获得化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的关于盐酸甲氧氯普胺（以下简称"药品"）的《化学原料药上 市申请批准通知书》（证书编号：2025YS00820）。现将有关情况公告如下： 一、药品的基本情况 药品名称：盐酸甲氧氯普胺 登记号：Y20230001040 规格：12kg/桶 四、风险提示 由于医药产品的销售受国家政策、市场需求、同类型药品市场竞争等因素的 影响，未来该产品销售情况存在不确定性，敬请广大投资者谨慎决策，注意防范 投资风险。 生产企业：湖北亨迪药业股份有限公司 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品的其他相关情况 盐酸甲氧氯普胺是一种多巴胺受体拮抗剂，主要用于缓解恶心、呕 ...

Group 1 - The core point of the article is that Hendi Pharmaceutical announced the approval of several proposals, including changes to the company's registered capital and amendments to the company’s articles of association [2] Group 2 - The second meeting of the second board of directors was held on the evening of September 2, where the proposals were reviewed and approved [2] - The company will proceed with the necessary business registration changes following the approval of the proposals [2]

Group 1 - The company, Hendi Pharmaceutical, announced that it will hold its second extraordinary general meeting of shareholders on September 18, 2025 [2] - The agenda for the meeting includes proposals to change the company's registered capital, amend the articles of association, and handle business registration changes [2] - Additionally, the meeting will review proposals to revise certain governance systems of the company [2]

Group 1 - The core point of the article is that Hendi Pharmaceutical announced the approval of changes to its registered capital and amendments to its articles of association during the 14th meeting of the second supervisory board [2] Group 2 - The company will proceed with the necessary business registration changes following the approval [2]

Core Points - The document outlines the rules for the shareholders' meeting of Hubei Hendi Pharmaceutical Co., Ltd, aiming to ensure compliance with laws and regulations while protecting shareholders' rights [1][2][3] Group 1: General Provisions - The rules are established to regulate the behavior of the company and ensure efficient decision-making at shareholders' meetings [1] - Shareholders' meetings can be classified into annual and temporary meetings, with annual meetings required to be held within six months after the end of the previous fiscal year [1][2] - The company must report to the China Securities Regulatory Commission and the stock exchange if it cannot convene a shareholders' meeting within the stipulated time [2] Group 2: Rights and Responsibilities - The shareholders' meeting is the company's authority body, exercising powers such as electing directors, approving profit distribution plans, and making decisions on capital changes [8][9] - The company must hire a lawyer to provide legal opinions on the legality of the meeting's procedures and results [2][3] Group 3: Transactions and Approvals - Certain transactions, such as external guarantees and significant asset purchases, require approval from the shareholders' meeting if they exceed specified thresholds [4][5][6] - The rules specify that transactions involving guarantees exceeding 30% of the company's audited total assets must be approved by the shareholders' meeting [4] Group 4: Shareholder Proposals and Notifications - Shareholders holding more than 1% of shares can propose temporary items for discussion at the shareholders' meeting, which must be notified within two days of receipt [35][36] - Notifications for annual meetings must be sent at least 20 days in advance, while temporary meetings require a 15-day notice [37][38] Group 5: Meeting Procedures - The shareholders' meeting must be held at the company's registered location, and provisions must be made for remote participation [42][43] - The meeting must be presided over by the chairman or a designated director, and all shareholders have the right to attend and vote [50][51] Group 6: Voting and Resolutions - Shareholders must express their votes as either in favor, against, or abstaining, and the results must be publicly disclosed [59][62] - The company must ensure that resolutions passed at the shareholders' meeting are implemented within two months [67]

Core Points - The company has established a fundraising management system to regulate the management and use of raised funds, ensuring investor interests are maximized [1][2] - The system is applicable to funds raised through stock issuance or other equity-like securities, excluding funds raised for equity incentive plans [1] Fundraising Management System - The board of directors must thoroughly evaluate the feasibility of fundraising investment projects to ensure good market prospects and profitability, thereby mitigating investment risks [2] - The company is required to establish internal control systems for the storage, management, use, and supervision of raised funds, including clear approval authority and decision-making processes [2][3] - A special account for raised funds must be opened with a commercial bank, and funds should be stored in this account exclusively [3][4] - A tripartite supervision agreement must be signed with the sponsor and the commercial bank within one month of the funds being in place [3][4] Use of Raised Funds - Funds must be used according to the investment plan outlined in the issuance application documents, primarily for the main business [5] - The company is prohibited from using raised funds for financial investments, such as trading financial assets or lending [5][6] - The board must conduct a comprehensive review of the investment projects every six months, and any significant deviations from the investment plan must be disclosed [6][7] - If a project is delayed or not completed as planned, the company must provide reasons and a revised investment plan [6][7] Management of Surplus and Idle Funds - Surplus funds must be used for ongoing or new projects, or for share buybacks, and a plan for their use must be disclosed [8][9] - Idle funds can be temporarily used to supplement working capital, with strict limits on the duration and amount [8][9] - Cash management of idle funds must be conducted through designated accounts, ensuring that it does not affect the normal progress of investment projects [10][20] Reporting and Supervision - The company must disclose the actual use of raised funds accurately and promptly, especially if there are significant impacts on the investment plan [33][39] - The sponsor or independent financial advisor is responsible for ongoing supervision of the management and use of raised funds, with regular audits and reports required [20][22] - Any misuse or unauthorized changes in the use of raised funds must be reported and rectified promptly [23][39]